Mammary adenocarcinoma is the most common cancer among women in the United States, with an estimated 175,000 new cases occurring in 1993. Currently, one out of nine American women will develop breast cancer in her lifetime. The rate of breast cancer incidence has increased 2-3% per year over the past decade in both premenopausal and postmenopausal women. Breast cancer is the second major cause of cancer deaths in women, and approximately 45,000 deaths from breast cancer are anticipated in 1993. The integration of basic science research with clinical investigations is critical in addressing key issues in breast cancer etiology and therapy. The P20 Program Development Grant on Breast Cancer focuses on molecular targets In breast cancer etiology and therapy and will involve two centers here at The Ohio State University. The OSU Comprehensive Cancer Center (OSUCCC) and the Center's Arthur G. James Cancer Hospital and Research Institute (CHRI) provide important opportunities for multidisciplinary laboratory and clinical research interactions in breast cancer. The Center for Molecular Environmental Health (CMEH) at The Ohio State University emphasizes research in molecular toxicology, molecular epidemiology, and molecular pathology. Furthermore, a core of key faculty and researchers in the OSUCCC, the CMEH, and associated Colleges of Medicine, Pharmacy, Veterinary Medicine, and Biological Sciences are committed to breast cancer research and the development of translational studies in breast cancer. The nucleus of investigators of this P20 Program Development Grant on Breast Cancer are involved in several OSUCCC Basic Sciences (Hormones and Cancer, Carcinogenesis, Therapeutics, Gene Expression) and Clinical Programs (Surgical Oncology, Hematology/Oncology). Research strengths in areas of endocrinology, developmental therapeutics, gene expression, and carcinogenesis permit unique opportunities for integration of this research into new programs focusing on translational research objectives in breast cancer etiology and therapy. The overall theme of the P20 Program Development Grant addresses molecular targets In breast cancer etiology and therapy. The research projects center around the interactions of small molecules (steroids, natural products, synthetic agents, environmental agents) and large molecules (peptide and protein agonists/antagonists, antibodies) with critical biomolecular targets in breast cancer (enzymes, receptors, DNA). Research projects and developmental programs of the proposal have several important multidisciplinary focuses in the areas of breast cancer etiology and therapy. Translational research objectives of the projects focus on integration and transfer of the basic sciences in these areas into clinical practice in the four year period of the P20 proposal. The major components of this P20 Program Development Grant are (1) description of the program leaders, (2) discussions on the investigators involved, their research activities, and developments of the program, (3) the development plan emphasizing new interdisciplinary projects in environmental factors in breast cancer and development of new breast cancer therapies, (4) budgets, and (5) supporting documents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA066193-02
Application #
2109478
Study Section
Special Emphasis Panel (SRC (05))
Project Start
1994-09-30
Project End
1998-09-29
Budget Start
1995-09-30
Budget End
1996-09-29
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lynch, M A; Petrel, T A; Song, H et al. (2001) Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells. Gene Expr 9:157-71
Bhat, A S; Whetstone, J L; Brueggemeier, R W (2000) A method for the rapid synthesis of benzopyrone libraries employing a resin capture strategy. J Comb Chem 2:597-9
Parrett, M L; Abou-Issa, H M; Alshafie, G et al. (1999) Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. Anticancer Res 19:5079-85
Robertson, F M; Parrett, M L; Joarder, F S et al. (1998) Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122:165-75
Lovely, C J; Bhat, A S; Coughenour, H D et al. (1997) Synthesis and biological evaluation of 4-(hydroxyalkyl)estradiols and related compounds. J Med Chem 40:3756-64
Brueggemeier, R W; Gilbert, N E; Gu, X et al. (1997) Aromatase inhibition in JAr choriocarcinoma cells by 7alpha-arylaliphatic androgens. J Steroid Biochem Mol Biol 61:73-7
Burak Jr, W E; Quinn, A L; Farrar, W B et al. (1997) Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Breast Cancer Res Treat 44:57-64
Wani, G; Noyes, I; Milo, G E et al. (1997) Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression. Mol Med 3:273-83
Lovely, C J; Gilbert, N E; Liberto, M M et al. (1996) 2-(Hydroxyalkyl)estradiols: synthesis and biological evaluation. J Med Chem 39:1917-23